1 |
SEMPLE J W, PROVAN D, GARVEY M B, et al. Recent progress in understanding the pathogenesis of immune thrombocytopenia[J]. Curr Opin Hematol, 2010, 17(6): 590-595.
|
2 |
REEMS J A, PINEAULT N, SUN S J. In vitro megakaryocyte production and platelet biogenesis: state of the art[J]. Transfus Med Rev, 2010, 24(1): 33-43.
|
3 |
GLENNIE S, SOEIRO I, DYSON P J, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells[J]. Blood, 2005, 105(7): 2821-2827.
|
4 |
TABERA S, PÉREZ-SIMÓN J A, DÍEZ-CAMPELO M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes[J]. Haematologica, 2008, 93(9): 1301-1309.
|
5 |
TASSO R, ILENGO C, QUARTO R, et al. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis[J]. Invest Ophthalmol Vis Sci, 2012, 53(2): 786-793.
|
6 |
MA J, NING Y N, XU M, et al. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia[J]. Blood, 2013, 122(12): 2074-2082.
|
7 |
PÉREZ-SIMÓN J A, TABERA S, SARASQUETE M E, et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura[J]. Cytotherapy, 2009, 11(6): 698-705.
|
8 |
ZHANG D L, LI H Y, MA L, et al. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia[J]. Autoimmunity, 2014, 47(8): 519-529.
|
9 |
王君颖, 李昕, 殷婷玉, 等. 免疫性血小板减少症患者来源的骨髓间充质细胞对巨核细胞生物学行为的影响[J]. 上海交通大学学报(医学版), 2018, 38(6): 616-623.
|
|
WANG J Y, LI X, YIN T Y, et al. Effects of bone marrow mesenchymal cells from immune thrombocytopenia patients on the biological behaviors of megakaryocytes[J]. J Shanghai Jiao Tong Univ (Med Sci), 2018, 38(6): 616–625.
|
10 |
XIAO J H, ZHANG C R, ZHANG Y C, et al. Transplantation of adipose-derived mesenchymal stem cells into a murine model of passive chronic immune thrombocytopenia[J]. Transfusion, 2012, 52(12): 2551-2558.
|
11 |
ZHANG P, ZHANG G, LIU X, et al. Mesenchymal stem cells improve platelet counts in mice with immune thrombocytopenia[J]. J Cell Biochem, 2019. DOI: 10.1002/jcb.28405.
|
12 |
WANG X H, YIN X G, SUN W, et al. Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: a two-year follow-up[J]. Exp Ther Med, 2017, 13(5): 2255-2258.
|
13 |
LEE S, KIM H S, ROH K H, et al. DNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells[J]. Sci Rep, 2015, 5: 8020.
|
14 |
LIU S Y, SHAN N N. DNA methylation plays an important role in immune thrombocytopenia[J]. Int Immunopharmacol, 2020, 83: 106390.
|
15 |
ASSIS R I F, WIENCH M, SILVÉRIO K G, et al. RG108 increases NANOG and OCT4 in bone marrow-derived mesenchymal cells through global changes in DNA modifications and epigenetic activation[J]. PLoS One, 2018, 13(12): e0207873.
|
16 |
OH Y S, JEONG S G, CHO G W. Anti-senescence effects of DNA methyltransferase inhibitor RG108 in human bone marrow mesenchymal stromal cells[J]. Biotechnol Appl Biochem, 2015, 62(5): 583-590.
|
17 |
OH Y S, KIM S H, CHO G W. Functional restoration of amyotrophic lateral sclerosis patient-derived mesenchymal stromal cells through inhibition of DNA methyltransferase[J]. Cell Mol Neurobiol, 2016, 36(4): 613-620.
|
18 |
ZHOU H, HOU Y, LIU X N, et al. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia[J]. Thromb Haemost, 2015, 113(5): 1021-1034.
|
19 |
RODEGHIERO F, STASI R, GERNSHEIMER T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11): 2386-2393.
|
20 |
LAMBERT M P, GERNSHEIMER T B. Clinical updates in adult immune thrombocytopenia[J]. Blood, 2017, 129(21): 2829-2835.
|
21 |
SHEN Y, NILSSON S K. Bone, microenvironment and hematopoiesis[J]. Curr Opin Hematol, 2012, 19(4): 250-255.
|
22 |
SONG Y, WANG Y T, HUANG X J, et al. Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia[J]. Ann Hematol, 2016, 95(6): 959-965.
|
23 |
TAO Y L, SONG D X, ZHANG F Y, et al. Transplantation of bone-marrow-derived mesenchymal stem cells into a murine model of immune thrombocytopenia[J]. Blood Coagul Fibrinolysis, 2017, 28(8): 596-601.
|
24 |
LI H Y, XUAN M, YANG R C. DNA methylation and primary immune thrombocytopenia[J]. Semin Hematol, 2013, 50(Suppl 1): S116-S126.
|
25 |
WANG J H, YI Z H, WANG S Y, et al. The effect of decitabine on megakaryocyte maturation and platelet release[J]. Thromb Haemost, 2011, 106(2): 337-343.
|
26 |
HAN P P, HOU Y, ZHAO Y J, et al. Low-dose decitabine modulates T cell homeostasis and restores immune tolerance in immune thrombocytopenia[J]. Blood, 2021, 138(8): 674-688.
|
27 |
WANG Y, WANG F X, WEN S P, et al. Artesunate-enhanced apoptosis of human high-risk myelodysplastic cells induced by the DNA methyltransferase inhibitor decitabine[J]. Oncol Lett, 2015, 9(6): 2449-2454.
|
28 |
ZHANG G, GAO X H, ZHAO X Y, et al. Decitabine inhibits the proliferation of human T-cell acute lymphoblastic leukemia molt4 cells and promotes apoptosis partly by regulating the PI3K/AKT/mTOR pathway[J]. Oncol Lett, 2021, 21(5): 340.
|
29 |
WANG L, AMOOZGAR Z, HUANG J, et al. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model[J]. Cancer Immunol Res, 2015, 3(9): 1030-1041.
|
30 |
RÜGER B M, BUCHACHER T, GIUREA A, et al. Vascular morphogenesis in the context of inflammation: self-organization in a fibrin-based 3D culture system[J]. Front Physiol, 2018, 9: 679.
|
31 |
ELMORE S. Apoptosis: a review of programmed cell death[J]. Toxicol Pathol, 2007, 35(4): 495-516.
|
32 |
FERRI K F, KROEMER G. Mitochondria: the suicide organelles[J]. BioEssays, 2001, 23(2): 111-115.
|